Zobrazeno 1 - 10
of 194
pro vyhledávání: '"es-sclc"'
Autor:
Jian Zhang, Aiqin Gao, Shuyun Wang, Yanxin Sun, Jiake Wu, Dahai Wang, Yihui Ge, Juan Li, Haifeng Sun, Qinglei Cheng, Yuping Sun
Publikováno v:
Respiratory Research, Vol 25, Iss 1, Pp 1-8 (2024)
Abstract Background Patients receiving PD-(L)1 inhibitors frequently encounter unusual side effects known as immune-related adverse events (irAEs). However, the correlation of irAEs development with clinical response in small cell lung cancer (SCLC)
Externí odkaz:
https://doaj.org/article/81edf98278c9466d9563b891d6a4d6fb
Autor:
Wenwen Kang, Jing Cheng, Luyun Pan, Ping Zhan, Hongbing Liu, Tangfeng Lv, Hedong Han, Yong Song
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
ObjectivesDifferences in clinicopathological characteristics of extensive-stage small cell lung cancer (ES-SCLC) patients may influence the immune response. This study aims to evaluate the heterogeneity of response to first-line chemoimmunotherapy be
Externí odkaz:
https://doaj.org/article/f6d49ef5e0f74481ac6d26a19845d157
Autor:
Dawei Chen, Bing Zou, Butuo Li, Aiqin Gao, Wei Huang, Qian Shao, Xiangjiao Meng, Pinliang Zhang, Xiaoyong Tang, Xudong Hu, Yan Zhang, Jun Guo, Changhong Zhao, Jiajia Yuan, Qian Li, Changbin Zhu, Jinming Yu, Linlin Wang
Publikováno v:
EClinicalMedicine, Vol 75, Iss , Pp 102795- (2024)
Summary: Background: This phase II prospective trial aimed to investigate the efficacy and safety of adebrelimab (PD-L1 antibody) plus first-line chemotherapy followed by sequential thoracic radiotherapy (TRT) combined with adebrelimab in extensive-s
Externí odkaz:
https://doaj.org/article/ed0b645bf07d4a3a8629b1e6c2966f9c
Publikováno v:
Thoracic Cancer, Vol 15, Iss 11, Pp 938-943 (2024)
Abstract Background Consolidative thoracic radiotherapy (cTRT) has previously shown benefit to patients with extensive stage small cell lung cancer (ES‐SCLC) who respond to chemotherapy. However, the optimum dose of cTRT is unknown. The purpose of
Externí odkaz:
https://doaj.org/article/c6638c286b6148fab54d918284196382
Publikováno v:
Cancer Management and Research, Vol Volume 16, Pp 177-183 (2024)
Fei Cai,1,2,* Di Wu,3,* Junling Liu,1 Shuxi Song,1 Jingyu Li,1 Zhendong Zheng,1 Long Xu1 1Department of Oncology, General Hospital of Northern Theater Command, Shenyang, Liaoning, People’s Republic of China; 2Beifang Hospital of China Medic
Externí odkaz:
https://doaj.org/article/63d3768097904731a17a9fbd2e7a3bb0
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
ObjectiveTo determine the cost-effectiveness of imported immune checkpoint inhibitors (ICIs) such as atezolizumab and durvalumab, and domestic ICIs like serplulimab and adebrelimab, in combination with chemotherapy for extensive-stage small cell lung
Externí odkaz:
https://doaj.org/article/27b729f3859d4633a2b39201519ce840
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
While the incidence of small-cell lung cancer is low, it has a poor prognosis. Patients with extensive small-cell lung cancer account for about 70% of all cases of small-cell lung cancer, with a median overall survival duration of 8–13 months and a
Externí odkaz:
https://doaj.org/article/b8df586aee9a43fba9eb7f7cfa058f97
Autor:
Bo Zhang, Hua Zhong, Chunlei Shi, Zhiqiang Gao, Runbo Zhong, Aiqin Gu, Weimin Wang, Tianqing Chu, Liwen Xiong, Wei Zhang, Huimin Wang, Xueyan Zhang, Baohui Han
Publikováno v:
The Clinical Respiratory Journal, Vol 17, Iss 12, Pp 1361-1367 (2023)
Abstract Introduction Durvalumab is a check‐point inhibitor against programmed death ligand‐1 (PD‐L1), and anlotinib is a new orally administered multitarget tyrosine kinase inhibitor (TKI). Both agents have been approved in China. Preclinical
Externí odkaz:
https://doaj.org/article/a5f8528abb824329a4d37c54d296c13e
Publikováno v:
Risk Management and Healthcare Policy, Vol Volume 16, Pp 2521-2529 (2023)
Dongchu Zhou,1 Xinrui Dong,1 Zhen Zhou,2 Qiao Liu1 1Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, People’s Republic of China; 2School of Public Health and Preventive Medicine, Monash University, Melbourn
Externí odkaz:
https://doaj.org/article/c01585a78e67476990bba6eb85d2623f
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.